Matthew K. Tollefson

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.”.

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3172

N/A

0DataRank · unranked

1 citations

Tanner Miest, Paul R. Young, Mark L. Gonzalgo, Stephen A. Boorjian, Matthew K. Tollefson +15 more

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.509

N/A

0DataRank · unranked

8 citations

Bradley C. Leibovich, Tanner Miest, Stephen Bardot, Paul R. Young, Stephen A. Boorjian +14 more